Xiaonan Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3011275/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020, 583, 437-440.	13.7	746
2	Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet, The, 2013, 381, 2273-2279.	6.3	308
3	Long-term functional maintenance of primary human hepatocytes in vitro. Science, 2019, 364, 399-402.	6.0	147
4	Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clinical Immunology, 2008, 128, 400-408.	1.4	134
5	PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology, 2017, 66, 398-415.	3.6	101
6	Hepatitis B virus polymerase impairs interferon-α-induced STA T activation through inhibition of importin-α5 and protein kinase C-Î′. Hepatology, 2013, 57, 470-482.	3.6	99
7	In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. Journal of Clinical Investigation, 2016, 126, 1079-1092.	3.9	83
8	Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. Journal of General Virology, 2007, 88, 3260-3269.	1.3	81
9	Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: Evaluation of antiviral efficacy in a murine infection model. Antiviral Research, 2013, 97, 264-269.	1.9	79
10	Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Scientific Reports, 2017, 7, 43446.	1.6	68
11	Predictive model for inflammation grades of chronic hepatitis B: Largeâ€scale analysis of clinical parameters and gene expressions. Liver International, 2017, 37, 1632-1641.	1.9	62
12	Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Letters, 2006, 580, 4392-4400.	1.3	58
13	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerging Microbes and Infections, 2020, 9, 1988-1996.	3.0	58
14	Label-free Proteomic Analysis of Exosomes Derived from Inducible Hepatitis B Virus-Replicating HepAD38 Cell Line. Molecular and Cellular Proteomics, 2017, 16, S144-S160.	2.5	56
15	Functional Comparison of Interferonâ€Î± Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferonâ€Î± and Interferonâ€Î³ Signaling. Hepatology, 2021, 73, 486-502.	3.6	51
16	Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. Scientific Reports, 2015, 5, 16459.	1.6	49
17	Extracellular Hepatitis B Virus RNAs Are Heterogeneous in Length and Circulate as Capsid-Antibody Complexes in Addition to Virions in Chronic Hepatitis B Patients. Journal of Virology, 2018, 92, .	1.5	45
18	A two-step lineage reprogramming strategy to generate functionally competent human hepatocytes from fibroblasts. Cell Research, 2019, 29, 696-710.	5.7	43

XIAONAN ZHANG

#	Article	IF	CITATIONS
19	Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. Journal of General Virology, 2009, 90, 2686-2694.	1.3	41
20	Plasma Microrna Profile as a Predictor of Early Virological Response to Interferon Treatment in Chronic Hepatitis B Patients. Antiviral Therapy, 2012, 17, 1243-1253.	0.6	33
21	Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. Emerging Microbes and Infections, 2014, 3, 1-9.	3.0	32
22	Differentially Expressed Intrahepatic Genes Contribute to Control of Hepatitis B Virus Replication in the Inactive Carrier Phase. Journal of Infectious Diseases, 2018, 217, 1044-1054.	1.9	30
23	Comparison of Circulating, Hepatocyte Specific Messenger RNA and microRNA as Biomarkers for Chronic Hepatitis B and C. PLoS ONE, 2014, 9, e92112.	1.1	30
24	Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses. Vaccine, 2009, 28, 187-194.	1.7	28
25	Extra-pulmonary viral shedding in H7N9 Avian Influenza patients. Journal of Clinical Virology, 2015, 69, 30-32.	1.6	28
26	Direct interaction between α-actinin and hepatitis C virus NS5B. FEBS Letters, 2003, 554, 289-294.	1.3	25
27	Genetic and phenotypic characterization of Candida albicans strains isolated from infectious disease patients in Shanghai. Journal of Medical Microbiology, 2015, 64, 74-83.	0.7	24
28	MicroRNA-939 restricts Hepatitis B virus by targeting Jmjd3-mediated and C/EBPα-coordinated chromatin remodeling. Scientific Reports, 2016, 6, 35974.	1.6	19
29	Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. Antiviral Research, 2018, 152, 45-52.	1.9	16
30	A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification. Scientific Reports, 2021, 11, 4405.	1.6	15
31	Desflurane Preconditioning Inhibits Endothelial Nuclear Factor-κ-B Activation by Targeting the Proximal End of Tumor Necrosis Factor-α Signaling. Anesthesia and Analgesia, 2008, 106, 1473-1479.	1.1	14
32	Infection of inbred BALB/c and C57BL/6 and outbred Institute of Cancer Research mice with the emerging H7N9 avian influenza virus. Emerging Microbes and Infections, 2013, 2, 1-7.	3.0	14
33	Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients. Scientific Reports, 2017, 7, 15658.	1.6	14
34	Animal Models for the Study of Hepatitis B Virus Pathobiology and Immunity: Past, Present, and Future. Frontiers in Microbiology, 2021, 12, 715450.	1.5	14
35	Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B. BMC Gastroenterology, 2017, 17, 140.	0.8	12
36	Probing the spatiotemporal patterns of HBV multiplication reveals novel features of its subcellular processes. PLoS Pathogens, 2021, 17, e1009838.	2.1	12

XIAONAN ZHANG

#	Article	IF	CITATIONS
37	Co-infection in COVID-19, a cohort study. Journal of Infection, 2021, 82, 414-451.	1.7	11
38	Computational analyses of JAK1 kinase domain: Subtle changes in the catalytic cleft influence inhibitor specificity. Biochemical and Biophysical Research Communications, 2008, 370, 72-76.	1.0	10
39	PCR for Detection of Oseltamivir Resistance Mutation in Influenza A(H7N9) Virus. Emerging Infectious Diseases, 2014, 20, 847-849.	2.0	10
40	Oral Administered Particulate Yeast-Derived Glucan Promotes Hepatitis B Virus Clearance in a Hydrodynamic Injection Mouse Model. PLoS ONE, 2015, 10, e0123559.	1.1	10
41	Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV. Journal of Experimental Medicine, 2022, 219, .	4.2	10
42	The discovery and characterization of a novel scaffold as a potent hepatitis C virus inhibitor. Chemical Communications, 2016, 52, 3340-3343.	2.2	9
43	A novel recombinant cccDNA-based mouse model with long term maintenance of rcccDNA and antigenemia. Antiviral Research, 2020, 180, 104826.	1.9	9
44	An infectious clone of enterovirus 71(EV71) that is capable of infecting neonatal immune competent mice without adaptive mutations. Emerging Microbes and Infections, 2020, 9, 427-438.	3.0	9
45	Visualization of Macrophage Lytic Cell Death During Mycobacterial Infection in Zebrafish Embryos via Intravital Microscopy. Journal of Visualized Experiments, 2019, , .	0.2	7
46	Clinical relevance of the in situ assay for HBV DNA: a cross-sectional study in patients with chronic hepatitis B. Journal of Clinical Pathology, 2020, 73, 813-818.	1.0	7
47	Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. International Journal of STD and AIDS, 2017, 28, 380-388.	0.5	6
48	Establishment of a fluorescent in situ hybridization assay for imaging hepatitis B virus nucleic acids in cell culture models. Emerging Microbes and Infections, 2017, 6, 1-6.	3.0	6
49	An integrated software for virus community sequencing data analysis. BMC Genomics, 2020, 21, 363.	1.2	5
50	In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma. Diagnostic Pathology, 2022, 17, 11.	0.9	4
51	A random PCR screening system for the identification of type 1 human herpes simplex virus. Journal of Virological Methods, 2009, 161, 91-97.	1.0	3
52	A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles. Medicine (United States), 2016, 95, e2511.	0.4	3
53	Evaluation of the in situ assay for HBV DNA. Medicine (United States), 2021, 100, e27220.	0.4	3
54	The role of hepatitis B virus surface proteins in regulating the maturation and secretion of complete and incomplete virions. Journal of General Virology, 2022, 103, .	1.3	3

#	Article	IF	CITATIONS
55	纳米å"测å⁰技术在é‡ç—‡æ–°å†è,ºç,Žæ,£è€ç»§å'感染è⁻Šæ–ä,的应用. Zhejiang Da Xue Xue Bao	Yi Xue Ban	= J ournal of
56	Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection.	0.5	0